Filtered By:
Therapy: Gene Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 224 results found since Jan 2013.

Apolipoprotein A-I vascular gene therapy reduces vein-graft atherosclerosis
Mol Ther Methods Clin Dev. 2023 Aug 22;30:558-572. doi: 10.1016/j.omtm.2023.08.018. eCollection 2023 Sep 14.ABSTRACTCoronary artery venous bypass grafts typically fail because of atherosclerosis driven by lipid and macrophage accumulation. Therapy for vein-graft atherosclerosis is limited to statin drugs, which are only modestly effective. We hypothesized that transduction of vein-graft endothelium of fat-fed rabbits with a helper-dependent adenovirus expressing apolipoprotein AI (HDAdApoAI) would reduce lipid and macrophage accumulation. Fat-fed rabbits received bilateral external jugular vein-to-carotid artery interposit...
Source: Atherosclerosis - September 11, 2023 Category: Cardiology Authors: Lianxiang Bi Bradley K Wacker Kaushik Komandur Nicole Sanford David A Dichek Source Type: research

Fight Aging! Newsletter, August 14th 2023
This study demonstrates just how vital the thymus is to maintaining adult health." « Back to Top Does Amyloid-β Aggregation Cause Broad Disruption of Proteostasis? https://www.fightaging.org/archives/2023/08/does-amyloid-%ce%b2-aggregation-cause-broad-disruption-of-proteostasis/ Researchers here speculate on the ability of insoluble amyloid-β aggregates to be broadly disruptive of the solubility of many other proteins, and thus disruptive to cell and tissue function. Is this important in aging? The evidence here shows the existence of the mechanism in a lower species, but that doesn't n...
Source: Fight Aging! - August 13, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Site-Specific Bioorthogonal Activation of DNAzymes for On-Demand Gene Therapy
J Am Chem Soc. 2023 Aug 3. doi: 10.1021/jacs.3c05413. Online ahead of print.ABSTRACTRNA-cleaving DNAzymes hold great promise as gene silencers, and spatiotemporal control of their activity through site-specific reactions is crucial but challenging for on-demand therapy. We herein report a novel design of a bioorthogonally inducible DNAzyme that is deactivated by site-specific installation of bioorthogonal caging groups on the designated backbone sites but restores the activity via a phosphine-triggered Staudinger reduction. We perform a systematical screening for installing the caging groups on each backbone site in the ca...
Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Rong Wang Wenhan He Xin Yi Zhenkun Wu Xia Chu Jian-Hui Jiang Source Type: research

Ad hoc announcement pursuant to Art. 53 LR Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

Fight Aging! Newsletter, July 24th 2023
In this study, we tested the hypothesis that periodontal disease (PD) as a source of infection alters inflammatory activation and Aβ phagocytosis by the microglial cells. Experimental PD was induced using ligatures in C57BL/6 mice for 1, 10, 20, and 30 days to assess the progression of PD. Animals without ligatures were used as controls. Ligature placement caused progressive periodontal disease and bone resorption that was already significant on day 1 post-ligation and continued to increase until day 30. The severity of periodontal disease increased the frequency of activated microglia in the brains on day 30 by 36...
Source: Fight Aging! - July 23, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news

Fight Aging! Newsletter, July 3rd 2023
In this study, cultured adipose-derived stem cells (ASCs) were derived from subcutaneous white adipose tissue isolated from mice fed a normal diet. We performed senescence-associated-β-galactosidase (SA-β-gal) staining, real-time PCR, and Western blot to evaluate the levels related to cellular senescence markers. The mRNA expression levels of senescence markers were significantly increased in the later passages of ASCs. We show that light activation reduced the expression of senescent genes, and SA-β-Gal in all cells at passages. Moreover, the light-activated ASCs-derived exosomes decrease the expression of senes...
Source: Fight Aging! - July 2, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, May 22nd 2023
Conclusions to be Drawn A High Fat Diet Accelerates Atherosclerosis Less Directly than One Might Suspect How to Construct Measures of Biological Age A Long-Term Comparison of Metformin in Diabetics with Non-Diabetic Controls In Search of Distinctive Features of the Gut Microbiome in Long-Lived Individuals Greater Fitness in Humans Implies a Younger Epigenome and Transcriptome Intestinal Barrier Dysfunction as a Feature of Aging in Many Species NAFLD as an Age-Related Condition Towards Sensory Hair Cell Regeneration in the Inner Ear Raised Levels of PLG...
Source: Fight Aging! - May 21, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

FDA accepts application for Roche ’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluidIf approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries to treat nAMD and DME, with nearly one million doses distributed globallyBasel, 9 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY...
Source: Roche Investor Update - May 9, 2023 Category: Pharmaceuticals Source Type: news

Twist of fate: What happens when a top Parkinson ’s researcher gets the disease
SEVERAL YEARS AGO , Tim Greenamyre, a neuroscientist and physician who directs the Pittsburgh Institute for Neurodegenerative Diseases at the University of Pittsburgh (Pitt), began to notice unsettling symptoms in his own body. He couldn’t smell things. He was constipated. He was shouting and kicking in his sleep. His left arm didn’t swing when he walked. In July 2021, Greenamyre turned to a neurologist colleague to confirm the diagnosis he already suspected. He had Parkinson’s disease, an illness he has devoted himself to treating and trying to cure. Over the course of his long and productive career, the 67-...
Source: Science of Aging Knowledge Environment - May 4, 2023 Category: Geriatrics Source Type: research

Twist of fate: What happens when a top Parkinson ’s researcher gets the disease?
SEVERAL YEARS AGO , Tim Greenamyre, a neuroscientist and physician who directs the Pittsburgh Institute for Neurodegenerative Diseases at the University of Pittsburgh (Pitt), began to notice unsettling symptoms in his own body. He couldn’t smell things. He was constipated. He was shouting and kicking in his sleep. His left arm didn’t swing when he walked. In July 2021, Greenamyre turned to a neurologist colleague to confirm the diagnosis he already suspected. He had Parkinson’s disease, an illness he has devoted himself to treating and trying to cure. Over the course of his long and productive career, the 67-...
Source: Science of Aging Knowledge Environment - May 4, 2023 Category: Geriatrics Source Type: research

New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME
Post-hoc analyses from four phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)More Vabysmo patients with nAMD had absence of retinal fluid at 12 weeks in a post-hoc analysis from the phase III TENAYA and LUCERNE studiesDME patients treated with Vabysmo had less blood vessel leakage in the macula at 16 weeks in a post-hoc analysis from the phase III YOSEMITE and RHINE studiesBasel, 25 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that post-hoc data indicate treatment with Va...
Source: Roche Investor Update - April 25, 2023 Category: Pharmaceuticals Source Type: news